Investor Presentation First Nine Months of 2023
41
Investor presentation
First nine months of 2023
The total branded diabetes market has a global value of DKK
-410 billion annually
DKK
billion
500
Global diabetes market
DKK
The USA
billion
2022/2023 2021/2022 Growth at CER
300
+19%
+15%
207
+36%
408
200
162
400
118
+48%
-22%
81
-13%
342
100
34 40
14 15
41 25
0
300
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
DKK
Outside the USA
+40%
billion
200
171
300
+12%
-12%
+46%
111
116
201
180
99
200
-15%
90
100
-7%
48 55
60
+50%
-16%
+45%
100
65 70
53
35
34 40
49
35
0
Total
0
Insulin
GLP-1
DPP-4i
SGLT-2i
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
Source: Company announcements as of Q2 2023; 2022/2023 data based on Q3 2022 to Q2 2023 and 2021/2022 data based on Q3 2021 to Q2 2022
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
Novo NordiskⓇView entire presentation